Literature DB >> 10875809

The argument against sentinel node biopsy for malignant melanoma.

J M Thomas, E J Patocskai.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10875809      PMCID： PMC1127684          DOI： 10.1136/bmj.321.7252.3

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  14 in total

Review 1.  Lymphatic mapping and sentinel lymphadenectomy for melanoma.

Authors:  M C Kelley; D W Ollila; D L Morton
Journal:  Semin Surg Oncol       Date:  1998-06

2.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme.

Authors:  N Cascinelli; A Morabito; M Santinami; R M MacKie; F Belli
Journal:  Lancet       Date:  1998-03-14       Impact factor: 79.321

3.  Reliability of sentinel lymph node biopsy for staging melanoma.

Authors:  L Jansen; O E Nieweg; J L Peterse; C A Hoefnagel; R A Olmos; B B Kroon
Journal:  Br J Surg       Date:  2000-04       Impact factor: 6.939

4.  Sentinel lymphadenectomy for patients with clinical stage I melanoma.

Authors:  D L Morton
Journal:  J Surg Oncol       Date:  1997-12       Impact factor: 3.454

5.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.

Authors:  C M Balch; S J Soong; A A Bartolucci; M M Urist; C P Karakousis; T J Smith; W J Temple; M I Ross; W R Jewell; M C Mihm; R L Barnhill; H J Wanebo
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

6.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.

Authors:  J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

7.  Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991.

Authors:  A S Coates; C I Ingvar; K Petersen-Schaefer; H M Shaw; G W Milton; C J O'Brien; J F Thompson; W H McCarthy
Journal:  J Am Coll Surg       Date:  1995-04       Impact factor: 6.113

8.  Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients.

Authors:  C L Slingluff; K R Stidham; W M Ricci; W E Stanley; H F Seigler
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

9.  Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities.

Authors:  U Veronesi; J Adamus; D C Bandiera; O Brennhovd; E Caceres; N Cascinelli; F Claudio; R L Ikonopisov; V V Javorski; S Kirov; A Kulakowski; J Lacour; F Lejeune; Z Mechl; A Morabito; I Rodé; S Sergeev; E van Slooten; K Szczygiel; N N Trapeznikov; R I Wagner
Journal:  Cancer       Date:  1982-06-01       Impact factor: 6.860

10.  A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results.

Authors:  F H Sim; W F Taylor; J C Ivins; D J Pritchard; E H Soule
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860
View more
  5 in total

1.  Sentinel node biopsy for malignant melanoma. Having this biopsy gives psychological benefits.

Authors:  S S Rayatt; S Hettiaratchy; A Key; B W Powell
Journal:  BMJ       Date:  2000-11-18

Review 2.  Recent developments in plastic surgery.

Authors:  D Johnson; I H Whitworth
Journal:  BMJ       Date:  2002-08-10

3.  Completion lymphadenectomy may not increase in-transit disease in malignant melanoma.

Authors:  Robin Russell-Jones; Ciaran Healy; Ann-Marie Powell; Katharine Acland; Michael O'Doherty; Eduardo Calonje
Journal:  BMJ       Date:  2004-11-27

4.  [Sentinel lymph node excision (SLNE) and positron emission tomography in the staging of stage I-II melanoma patients].

Authors:  A Schäfer; R A Herbst; U Beiteke; S Lange-Ionescu; H Treckmann; D Löhlein; G Thiemann; B Theophil; E-W Schwarze; H-J Bartels; P J Frosch
Journal:  Hautarzt       Date:  2003-01-15       Impact factor: 0.751

Review 5.  Imaging of metastatic melanoma.

Authors:  D Michael King
Journal:  Cancer Imaging       Date:  2006-12-22       Impact factor: 3.909
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.